Alector Net Income Over Time
| ALEC Stock | USD 1.93 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alector Performance and Alector Correlation. Will Biotechnology sector continue expanding? Could Alector diversify its offerings? Factors like these will boost the valuation of Alector. If investors know Alector will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alector data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.86) | Earnings Share (1.06) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets |
Investors evaluate Alector using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Alector's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Alector's market price to deviate significantly from intrinsic value.
Understanding that Alector's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alector represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Alector's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Alector and related stocks such as Nkarta Inc, Cassava Sciences, and Fate Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTX | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (21.1 M) | (91.4 M) | (83.9 M) | (119.4 M) | (117.5 M) | (108.8 M) | (97.9 M) | (102.8 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| FATE | (13.4 M) | (13.4 M) | (14.2 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (255.1 M) | (160.9 M) | (186.3 M) | (167.6 M) | (159.3 M) |
| PEPG | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (76.9 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (117.9 M) | (116.9 M) | (105.2 M) | (100 M) |
| CRBP | (887) | (887) | (887) | (602.4 K) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (55.8 M) | (44.6 M) | (40.2 M) | (36.2 M) | (38 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
Alector and related stocks such as Nkarta Inc, Cassava Sciences, and Fate Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Alector financial statement analysis. It represents the amount of money remaining after all of Alector operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Alector | ALEC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 131 Oyster Point |
| Exchange | NASDAQ Exchange |
USD 1.93
Check out Alector Performance and Alector Correlation. For information on how to trade Alector Stock refer to our How to Trade Alector Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Alector technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.